# Antibody Drugs Sector Canonical URL: https://biopharmsignal.com/sector/antibody-drugs Antibody Drugs includes companies developing monoclonal antibodies or related antibody-based therapeutics. These assets are central to many oncology, immunology, and rare-disease franchises because they can offer target specificity and scalable biologic development paths. Companies currently grouped under Antibody Drugs: 16 ## Recent Sector News - 2026-09-03 12:30 EST — CRVS — [Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-2026-cantor-global-healthcare-conferenc-f8b7b9d5) — Source: Corvus Pharmaceuticals - 2026-09-01 20:15 EST — ANAB — [Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/ANAB/anaptys-announces-participation-at-the-h-c-wainwright-28th-annual-global-investm-370d596a) — Source: AnaptysBio, Inc. - 2026-09-01 12:00 EST — LEGN — [Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference](https://biopharmsignal.com/news/LEGN/legend-biotech-to-participate-in-the-morgan-stanley-global-healthcare-conference-9365884f) — Source: Legend Biotech Corporation - 2026-09-01 07:00 EST — GSK — [GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data](https://biopharmsignal.com/news/GSK/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positi-66e1968d) — Source: GSK plc - 2026-09-01 05:00 EST — ARGX — [argenx to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-6bddaa28) — Source: Argenx - 2026-08-27 12:50 EST — ARGX — [argenx Completes Acquisition of Forte Biosciences, Inc.](https://biopharmsignal.com/news/ARGX/argenx-completes-acquisition-of-forte-biosciences-inc-3e2a94cd) — Source: Argenx - 2026-08-27 11:30 EST — CRVS — [Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-announces-publication-in-blood-of-final-phase-1-data-from-ead9d01e) — Source: Corvus Pharmaceuticals - 2026-08-24 07:01 EST — GSK — [Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer](https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-accepted-for-priority-review-by-the-us-fda-for-dmmr-msi-h-l-2c5da49b) — Source: GSK plc - 2026-08-24 07:00 EST — GSK — [Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B](https://biopharmsignal.com/news/GSK/hibsago-bepirovirsen-approved-in-japan-as-first-and-only-functional-cure-for-chr-a5ecb369) — Source: GSK plc - 2026-08-20 11:30 EST — IFRX — [InflaRx Announces Participation in September Investor Conferences](https://biopharmsignal.com/news/IFRX/inflarx-announces-participation-in-september-investor-conferences-430b37b9) — Source: Inflarx NV - 2026-08-19 20:05 EST — REGN — [Regeneron Announces Investor Conference Presentations](https://biopharmsignal.com/news/REGN/regeneron-announces-investor-conference-presentations-4174227d) — Source: Regeneron Pharmaceuticals - 2026-08-19 17:58 EST — REGN — [Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)](https://biopharmsignal.com/news/REGN/pasatru-garetosmab-grts-first-and-only-fda-approved-treatment-demonstrating-redu-533dc642) — Source: Regeneron Pharmaceuticals - 2026-08-17 05:00 EST — ARGX — [argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis](https://biopharmsignal.com/news/ARGX/argenx-announces-positive-topline-results-from-phase-3-alkivia-trial-of-efgartig-763f8522) — Source: Argenx - 2026-08-11 11:00 EST — LEGN — [Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights](https://biopharmsignal.com/news/LEGN/legend-biotech-reports-second-quarter-2026-results-and-recent-highlights-e2e82cac) — Source: Legend Biotech Corporation - 2026-08-06 20:01 EST — CRVS — [Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-second-quarter-2026--e0de761b) — Source: Corvus Pharmaceuticals - 2026-08-06 11:48 EST — ARGX — [argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.](https://biopharmsignal.com/news/ARGX/argenx-announces-commencement-of-tender-offer-to-acquire-forte-biosciences-inc-ff1c7665) — Source: Argenx - 2026-08-06 11:30 EST — IFRX — [InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones](https://biopharmsignal.com/news/IFRX/inflarx-reports-second-quarter-2026-results-and-highlights-key-achievements-and--0d4f5d46) — Source: Inflarx NV - 2026-08-06 11:30 EST — CMPX — [Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CMPX/compass-therapeutics-reports-2026-second-quarter-financial-results-and-provides--7f8ce8b7) — Source: Compass Therapeutics - 2026-08-03 20:01 EST — ARGX — [argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026](https://biopharmsignal.com/news/ARGX/argenx-announces-extraordinary-general-meeting-of-shareholders-on-september-17-2-afc05e25) — Source: Argenx - 2026-07-31 11:00 EST — REGN — [Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation](https://biopharmsignal.com/news/REGN/regeneron-awards-150-000-to-winners-of-the-2026-regeneron-prize-for-creative-inn-b562f013) — Source: Regeneron Pharmaceuticals ## Companies - [AMAM](https://biopharmsignal.com/company/AMAM) — Ambrx Biopharma - [ANAB](https://biopharmsignal.com/company/ANAB) — AnaptysBio, Inc. - [ARGX](https://biopharmsignal.com/company/ARGX) — Argenx - [ARDS](https://biopharmsignal.com/company/ARDS) — Aridis Pharmaceuticals - [CMPX](https://biopharmsignal.com/company/CMPX) — Compass Therapeutics - [CRVS](https://biopharmsignal.com/company/CRVS) — Corvus Pharmaceuticals - [GMAB](https://biopharmsignal.com/company/GMAB) — Genmab - [GSK](https://biopharmsignal.com/company/GSK) — GSK plc - [HNSA](https://biopharmsignal.com/company/HNSA) — Hansa Biopharma AB - [IFRX](https://biopharmsignal.com/company/IFRX) — Inflarx NV - [LEGN](https://biopharmsignal.com/company/LEGN) — Legend Biotech Corporation - [HGEN](https://biopharmsignal.com/company/HGEN) — QHUMANIGEN INCD - [REGN](https://biopharmsignal.com/company/REGN) — Regeneron Pharmaceuticals - [SNY](https://biopharmsignal.com/company/SNY) — Sanofi - [XNCR](https://biopharmsignal.com/company/XNCR) — Xencor - [YMAB](https://biopharmsignal.com/company/YMAB) — Y-mAbs